FR22C1036I1 - PYRIMIDINE DERIVATIVES AS HIV INHIBITOR - Google Patents

PYRIMIDINE DERIVATIVES AS HIV INHIBITOR

Info

Publication number: FR22C1036I1
Authority: FR; France
Prior art keywords: pyrimidine derivatives; hiv inhibitor; hiv; inhibitor; pyrimidine
Prior art date: 2001-08-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR22C1036C

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-13

Filing date

2022-07-27

Publication date

2022-09-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26076978&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1036(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

US case filed in Delaware District Court litigation https://portal.unifiedpatents.com/litigation/Delaware%20District%20Court/case/1%3A20-cv-00189 Source: District Court Jurisdiction: Delaware District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.

2022-07-27 Application filed filed Critical

2022-09-09 Publication of FR22C1036I1 publication Critical patent/FR22C1036I1/en

Status Active legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

FR22C1036C 2001-08-13 2022-07-27 PYRIMIDINE DERIVATIVES AS HIV INHIBITOR Active FR22C1036I1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP01203090		2001-08-13
EP02077748		2002-06-10
EP10178189.6A EP2298761B1 (en)	2001-08-13	2002-08-09	Hiv inhibiting pyrimidines derivatives
PCT/EP2002/008953 WO2003016306A1 (en)	2001-08-13	2002-08-09	Hiv inhibiting pyrimidines derivatives
EP02764839A EP1419152B1 (en)	2001-08-13	2002-08-09	Hiv inhibiting pyrimidines derivatives

Publications (1)

Publication Number	Publication Date
FR22C1036I1 true FR22C1036I1 (en)	2022-09-09

Family

ID=26076978

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
FR12C0035C Active FR12C0035I2 (en)	2001-08-13	2012-05-22	PYRIMIDINE DERIVATIVES HIV INHIBITORS
FR12C0036C Active FR12C0036I2 (en)	2001-08-13	2012-05-25	PYRIMIDINE DERIVATIVES HIV INHIBITORS
FR22C1036C Active FR22C1036I1 (en)	2001-08-13	2022-07-27	PYRIMIDINE DERIVATIVES AS HIV INHIBITOR

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
FR12C0035C Active FR12C0035I2 (en)	2001-08-13	2012-05-22	PYRIMIDINE DERIVATIVES HIV INHIBITORS
FR12C0036C Active FR12C0036I2 (en)	2001-08-13	2012-05-25	PYRIMIDINE DERIVATIVES HIV INHIBITORS

Country Status (38)

Country	Link
US (8)	US7125879B2 (en)
EP (3)	EP2298761B1 (en)
JP (4)	JP2005507380A (en)
KR (2)	KR100969273B1 (en)
CN (2)	CN101816658B (en)
AP (1)	AP1610A (en)
AR (1)	AR036387A1 (en)
AT (1)	ATE517891T1 (en)
AU (1)	AU2002329238C1 (en)
BE (3)	BE2012C020I2 (en)
BR (3)	BR122015023612B8 (en)
CA (1)	CA2452217C (en)
CY (3)	CY1112331T1 (en)
DE (1)	DE122012000038I1 (en)
DK (2)	DK1419152T3 (en)
EA (1)	EA006656B1 (en)
EG (1)	EG24684A (en)
ES (3)	ES2923581T3 (en)
FR (3)	FR12C0035I2 (en)
HK (2)	HK1070066A1 (en)
HR (3)	HRP20192051B1 (en)
HU (5)	HU230192B1 (en)
IL (2)	IL160328A0 (en)
JO (1)	JO3429B1 (en)
LT (2)	LT3808743T (en)
LU (2)	LU92001I2 (en)
MX (1)	MXPA04001401A (en)
MY (1)	MY189572A (en)
NO (3)	NO327639B1 (en)
NZ (1)	NZ530951A (en)
OA (1)	OA12652A (en)
PA (1)	PA8552901A1 (en)
PL (2)	PL402388A1 (en)
PT (1)	PT1419152E (en)
SI (2)	SI3808743T1 (en)
UA (1)	UA78221C2 (en)
WO (1)	WO2003016306A1 (en)
ZA (1)	ZA200401159B (en)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3429B1 (en)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	Hiv inhibiting pyrimidines derivatives
US7638522B2 (en) *	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) *	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MY169670A (en) *	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
ES2322252T3 (en)	2002-03-13	2009-06-18	Janssen Pharmaceutica Nv	AMINODERIVED AS NEW HISTONA-DEACETILASA INHIBITORS.
AR039540A1 (en)	2002-05-13	2005-02-23	Tibotec Pharm Ltd	MICROBICIDE COMPOUNDS WITH PIRIMIDINE OR TRIAZINE CONTENT
MXPA05001096A (en)	2002-07-29	2005-11-23	Rigel Pharmaceuticals Inc	Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds.
AU2003266413B2 (en) *	2002-08-09	2009-04-02	Janssen Pharmaceutica N.V.	Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
NZ539823A (en) *	2002-11-28	2008-04-30	Schering Aktiengessellschaft	Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
EA010379B1 (en)	2003-02-07	2008-08-29	Янссен Фармацевтика Н.В.	Hiv inhibiting 1,2,4 triazines
US20070021449A1 (en) *	2003-02-07	2007-01-25	Jan Heeres	Pyrimidine derivatives for the prevention of hiv infection
CL2004000306A1 (en)	2003-02-20	2005-04-08	Tibotec Pharm Ltd	COMPOUNDS DERIVED FROM PYRIMIDINE REPLACED WITH INDANO; PROCESS FOR PREPARATION; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; PHARMACEUTICAL COMBINATION; AND ITS USE FOR THE TREATMENT OR PROFILAXIS OF AN INFECTIOUS DISEASE.
BRPI0412734A (en)	2003-07-17	2006-09-26	Tibotec Pharm Ltd	process for preparing particles containing an antiviral
JP4886511B2 (en)	2003-07-30	2012-02-29	ライジェルファーマシューティカルズ，インコーポレイテッド	Method for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CA2533320A1 (en) *	2003-08-15	2006-02-24	Novartis Ag	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
TWI365744B (en) *	2003-09-03	2012-06-11	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
CN100475815C (en) *	2003-09-25	2009-04-08	詹森药业有限公司	HIV-reproduction-inhibitive purinderivater
EP1781639B1 (en)	2004-07-28	2012-01-25	Janssen Pharmaceutica NV	Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
EP1797050B1 (en)	2004-08-10	2013-10-23	Janssen Pharmaceutica NV	Hiv inhibiting 1.2.4-triazin-6-one derivates
WO2007050087A1 (en)	2004-08-25	2007-05-03	Ardea Biosciences, Inc.	N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
ES2380604T3 (en)	2004-08-25	2012-05-16	Ardea Biosciences, Inc.	S-triazolyl alpha-mercaptoacetanilides as HIV reverse transcriptase inhibitors
EA011036B1 (en) *	2004-09-02	2008-12-30	Янссен Фармацевтика Н.В.	Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
ME01246B (en) *	2004-09-02	2013-06-20	Janssen Pharmaceutica Nv	Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
UA92469C2 (en) *	2004-09-02	2010-11-10	Янссен Фармацевтика Н.В.	Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
KR101284361B1 (en) *	2004-09-02	2013-07-15	얀센 파마슈티카 엔.브이.	Hydrochloride of 4-((4-(4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
WO2006024667A1 (en) *	2004-09-02	2006-03-09	Janssen Pharmaceutica N.V.	Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
TW200626592A (en)	2004-09-20	2006-08-01	Xenon Pharmaceuticals Inc	Heterocyclic derivatives and their use as therapeutic agents
TW200626139A (en)	2004-09-20	2006-08-01	Xenon Pharmaceuticals Inc	Heterocyclic derivatives and their use as therapeutic agents
MX2007003327A (en)	2004-09-20	2007-06-05	Xenon Pharmaceuticals Inc	Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase.
TW200626138A (en)	2004-09-20	2006-08-01	Xenon Pharmaceuticals Inc	Heterocyclic derivatives and their use as therapeutic agents
JP5149009B2 (en)	2004-09-20	2013-02-20	ゼノン・ファーマシューティカルズ・インコーポレイテッド	Pyridazine derivatives for inhibiting human stearoyl-CoA desaturase
AU2005286648A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CN101083994A (en)	2004-09-20	2007-12-05	泽农医药公司	Heterocyclic derivatives and their use as therapeutic agents
WO2006035069A1 (en) *	2004-09-30	2006-04-06	Tibotec Pharmaceuticals Ltd.	Hiv inhibiting 5-substituted pyrimidines
BRPI0516746A (en)	2004-09-30	2008-09-23	Tibotec Pharm Ltd	5-heterocyclyl pyrimidines for hiv inhibition
BRPI0515935B8 (en) *	2004-09-30	2021-05-25	Janssen Sciences Ireland Uc	heterocyclyl- or 5-carbo substituted pyrimidines for inhibition of hiv, and pharmaceutical composition
SI1814878T1 (en)	2004-11-24	2012-06-29	Rigel Pharmaceuticals Inc	Spiro-2, 4-pyrimidinediamine compounds and their uses
EP2161275A1 (en)	2005-01-19	2010-03-10	Rigel Pharmaceuticals, Inc.	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7906511B2 (en)	2005-03-31	2011-03-15	Santen Pharmaceutical Co., Ltd.	Cyclic compound having pyrimidinylalkylthio group
TW201414495A (en)	2005-04-04	2014-04-16	Tibotec Pharm Ltd	Prevention of HIV-infection
MX2007013715A (en)	2005-05-05	2008-01-28	Ardea Biosciences Inc	Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv.
WO2006125809A1 (en) *	2005-05-26	2006-11-30	Tibotec Pharmaceuticals Ltd	Process for preparing 4-[(1,6-dihydro-6-oxo-2-pyrimidinyl)amino benzonitrile
AU2006343359A1 (en)	2005-06-03	2007-11-15	Xenon Pharmaceuticals Inc.	Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
KR101312225B1 (en)	2005-06-08	2013-09-26	리겔 파마슈티칼스, 인크.	Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
CA2630717C (en)	2006-01-19	2015-02-24	Janssen Pharmaceutica N.V.	Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
ME01617B (en) *	2006-01-20	2014-09-20	Janssen R&D Ireland	Long term treatment of hiv- infection with tcm278
DE602007009508D1 (en)	2006-03-30	2010-11-11	Little Island Co Cork	HIV-INHIBITED 5- (HYDROXYMETHYLENE AND AMINOMETHYLENE) SUBSTITUTED PYRIMIDINES
DK2004632T3 (en)	2006-03-30	2014-06-16	Janssen R & D Ireland	HIV INHIBITIVE 5-AMIDOSUBSTITUTED PYRIMIDINES
HUE038797T2 (en)	2006-06-23	2018-11-28	Janssen Sciences Ireland Uc	Aqueous suspensions of tmc278
AU2014200819B2 (en) *	2006-06-23	2016-05-26	Janssen Sciences Ireland Uc	Aqueous suspensions of TMC278
AU2016219555B2 (en) *	2006-06-23	2017-08-10	Janssen Sciences Ireland Uc	Aqueous suspensions of TMC278
WO2008058285A2 (en)	2006-11-09	2008-05-15	Ardea Biosciences, Inc.	4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
EA019941B1 (en)	2006-12-08	2014-07-30	АйАрЭм ЭлЭлСи	Compounds and compositions as protein kinase inhibitors
WO2008071587A2 (en) *	2006-12-13	2008-06-19	F. Hoffmann-La Roche Ag	2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
ES2523863T3 (en)	2006-12-29	2014-12-02	Janssen R&D Ireland	HIV-inhibited 5,6-substituted pyrimidines
AU2007341227C1 (en)	2006-12-29	2013-08-29	Janssen Sciences Ireland Uc	HIV inhibiting 6-substituted pyrimidines
JP2010518014A (en) *	2007-01-31	2010-05-27	バーテックスファーマシューティカルズインコーポレイテッド	2-Aminopyridine derivatives useful as kinase inhibitors
TWI494133B (en)	2007-03-14	2015-08-01	Tibotec Pharm Ltd	Powders for reconstitution
DK2146779T3 (en)	2007-04-18	2016-11-28	Pfizer Prod Inc	Sulfonylamid derivatives to treat abnormal cell growth.
CN101679294B (en)	2007-05-30	2012-08-08	弗·哈夫曼-拉罗切有限公司	Non-nucleoside reverse transcriptase inhibitors
KR101294731B1 (en) *	2007-06-04	2013-08-16	삼성디스플레이 주식회사	Array substrate, display panel having the array substrate and method of manufacturing the array substrate
WO2009007441A2 (en) *	2007-07-12	2009-01-15	Tibotec Pharmaceuticals Ltd.	Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
CN101407476B (en) *	2007-10-12	2012-07-18	中国人民解放军军事医学科学院毒物药物研究所	M-bis(arene) polysubstituted aniline compound as non-nucleoside HIV reverse transcriptase inhibitor, and preparation and use thereof
AR069753A1 (en)	2007-11-27	2010-02-17	Ardea Biosciences Inc	1,2,4-TRIAZOL COMPOUNDS AND COMPOSITIONS, USEFUL IN THE MODULATION OF SANGUINEO URIC ACID LEVELS
EP2220091B1 (en)	2007-12-14	2012-07-25	Ardea Biosciences, Inc.	Reverse transcriptase inhibitors
US11351168B1 (en)	2008-06-27	2022-06-07	Celgene Car Llc	2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101892989B1 (en)	2008-06-27	2018-08-30	셀젠 카르 엘엘씨	Heteroaryl compounds and uses thereof
US8569337B2 (en)	2008-07-23	2013-10-29	Vertex Pharmaceuticals Incorporated	Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011000839A (en)	2008-07-23	2011-04-05	Vertex Pharma	Pyrazolopyridine kinase inhibitors.
WO2010011768A1 (en)	2008-07-23	2010-01-28	Vertex Pharmaceuticals Incorporated	Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010017350A1 (en)	2008-08-06	2010-02-11	Vertex Pharmaceuticals Incorporated	Aminopyridine kinase inhibitors
WO2010040275A1 (en) *	2008-10-09	2010-04-15	中国人民解放军军事医学科学院毒物药物研究所	The 2-(4-substituted phenylamino) polysubstituted pyridine compounds as the inhibitors of non-nucleoside hiv reverse transcriptase, praparation methods and uses thereof
CN101717364B (en) *	2008-10-09	2014-08-13	中国人民解放军军事医学科学院毒物药物研究所	Paradoximes as HIV reverse transcriptase inhibitor as well as preparation method and purpose thereof
EP2181991A1 (en)	2008-10-28	2010-05-05	LEK Pharmaceuticals D.D.	Novel salts of sunitinib
EP2186809A1 (en)	2008-11-13	2010-05-19	LEK Pharmaceuticals D.D.	New crystal form of sunitinib malate
EP2381961B1 (en)	2008-12-24	2016-09-14	Janssen Sciences Ireland UC	Implantable devices for treating hiv
US9908884B2 (en)	2009-05-05	2018-03-06	Dana-Farber Cancer Institute, Inc.	EGFR inhibitors and methods of treating disorders
EP2427464A1 (en)	2009-05-06	2012-03-14	Vertex Pharmaceuticals Incorporated	Pyrazolopyridines
WO2011094273A1 (en)	2010-01-27	2011-08-04	Vertex Pharmaceuticals Incorporated	Pyrazolopyridine kinase inhibitors
WO2011094290A1 (en)	2010-01-27	2011-08-04	Vertex Pharmaceuticals Incorporated	Pyrazolopyrimidine kinase inhibitors
JP2013518113A (en)	2010-01-27	2013-05-20	バーテックスファーマシューティカルズインコーポレイテッド	Pyrazolopyrazine kinase inhibitor
EA025176B1 (en) *	2010-01-27	2016-11-30	Вайв Хелткер Компани	Combination for treating hiv infection
EP2536696A1 (en) *	2010-02-18	2012-12-26	Concert Pharmaceuticals Inc.	Pyrimidine derivatives
US8367315B2 (en)	2010-03-05	2013-02-05	Adan Rios	Inactivation of reverse transcriptases by azido-diarylpyrimidines
JP6068340B2 (en)	2010-08-10	2017-01-25	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	Besylate of BTK inhibitor
JP5956999B2 (en)	2010-11-01	2016-07-27	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	Heteroaryl compounds and uses thereof
EP2635284B1 (en)	2010-11-01	2019-12-18	Celgene CAR LLC	Heterocyclic compounds and uses thereof
CA2816957A1 (en)	2010-11-07	2012-05-10	Targegen, Inc.	Compositions and methods for treating myelofibrosis
JP5957003B2 (en)	2010-11-10	2016-07-27	セルジーンアヴィロミクスリサーチ，インコーポレイテッド	Mutant selective EGFR inhibitor and use thereof
EA201691695A1 (en)	2010-11-19	2017-11-30	Джилид Сайэнс, Инк.	THERAPEUTIC COMPOSITIONS CONTAINING RILPIVIRIN HCL AND TENOFOVIRA DYSOPROXYL FUMARATE
WO2012125993A1 (en)	2011-03-17	2012-09-20	Teva Pharmaceutical Industries Ltd.	Solid state forms of rilpivirine base, and rilipivirine salts
US9126949B2 (en)	2011-04-25	2015-09-08	Hetero Research Foundation	Process for rilpivirine
KR102027287B1 (en)	2011-08-30	2019-10-01	씨에이치디아이 파운데이션, 인코포레이티드	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ES2680146T3 (en) *	2011-09-16	2018-09-04	Hetero Research Foundation	Rilpivirine Hydrochloride
TW201325593A (en)	2011-10-28	2013-07-01	Celgene Avilomics Res Inc	Methods of treating a BRUTON'S tyrosine kinase disease or disorder
EP2628732A1 (en)	2012-02-20	2013-08-21	Sandoz AG	Novel crystalline form of rilpivirine hydrochloride
WO2013087794A1 (en)	2011-12-14	2013-06-20	Sandoz Ag	Polymorph of rilpivirine hydrochloride and its use as antiviral
EP2604593A1 (en)	2011-12-14	2013-06-19	Sandoz AG	Polymorph of Rilpivirine hydrochloride and its use as antiviral
KR102081042B1 (en)	2012-03-15	2020-02-26	셀젠 카르 엘엘씨	Solid forms of an epidermal growth factor receptor kinase inhibitor
CA2866857C (en)	2012-03-15	2021-03-09	Celgene Avilomics Research, Inc.	Salts of an epidermal growth factor receptor kinase inhibitor
WO2013153161A2 (en)	2012-04-11	2013-10-17	Sandoz Ag	Novel polymorph of rilpivirine hydrochloride
WO2013153162A1 (en)	2012-04-11	2013-10-17	Sandoz Ag	Polymorph of rilpivirine hydrochloride
WO2013179105A1 (en) *	2012-06-01	2013-12-05	Laurus Labs Private Limited	Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
EP2872492B1 (en) *	2012-07-12	2018-01-31	Hetero Research Foundation	Process for the preparation of rilpivirine using a novel intermediate
WO2014072419A1 (en)	2012-11-08	2014-05-15	Universiteit Antwerpen	Novel anti-hiv compounds
EP2935226A4 (en)	2012-12-21	2016-11-02	Celgene Avilomics Res Inc	Heteroaryl compounds and uses thereof
TW201446745A (en)	2013-02-08	2014-12-16	Celgene Avilomics Res Inc	ERK inhibitors and uses thereof
US9914709B2 (en)	2013-06-21	2018-03-13	Yale University	Compositions and methods of treating HIV-1 infections using same
US9492471B2 (en)	2013-08-27	2016-11-15	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
ES2747633T3 (en) *	2014-07-17	2020-03-11	Chdi Foundation Inc	Combination of KMO 6- (3-chloro-4-cyclopropoxyphenyl) pyrimidine-4-carboxylic acid inhibitor with an antiviral agent for the treatment of HIV related neurological disorders
WO2016025561A1 (en)	2014-08-13	2016-02-18	Celgene Avilomics Research, Inc.	Forms and compositions of an erk inhibitor
WO2016046786A1 (en)	2014-09-26	2016-03-31	Glaxosmithkline Intellectual Property (No.2) Limited	Long acting pharmaceutical compositions
CZ201532A3 (en)	2015-01-21	2015-02-25	Zentiva, K.S.	Process for preparing extremely pure rilpivirine and salt thereof
CN104926829A (en) *	2015-06-08	2015-09-23	山东大学	Thieno miazines derivatives and preparation method and application thereof
EP4070787B1 (en)	2015-06-30	2023-03-01	Gilead Sciences, Inc.	Pharmaceutical formulations
CZ2015579A3 (en)	2015-08-27	2017-03-08	Zentiva, K.S.	The crystalline form of A rilpivirine adipate and method of its preparation
CN106187916B (en) *	2016-07-04	2018-08-21	宜昌人福药业有限责任公司	A method of effectively removing rilpivirine isomers
HRP20240118T1 (en)	2016-10-24	2024-04-12	Janssen Sciences Ireland Unlimited Company	Dispersible compositions
CN106749203B (en) *	2016-11-28	2020-04-10	洛阳聚慧医药科技有限公司	Pyrimidine heterocyclic compound, pyrimidine heterocyclic compound salt, preparation method and application
CN106588696B (en) *	2016-12-08	2018-12-25	西北师范大学	A kind of preparation method of trans- 'alpha ', ' bela '-unsaturated nitrile class compound
CN106905244B (en) *	2017-02-27	2019-08-16	武汉工程大学	Diaryl pyrimidine-diketone acid heterozygous HIV-1 inhibitor and preparation method thereof
CN113227103A (en)	2018-09-18	2021-08-06	尼坎医疗公司	Trisubstituted heteroaryl derivatives as SRC homologous-2 phosphatase inhibitors
CN109293581B (en) *	2018-09-21	2020-03-27	宜昌人福药业有限责任公司	Method for preparing rilpivirine hydrochloride isomer Z and impurity X and application of impurity X as pesticide in agriculture
EP3870568B1 (en)	2018-10-25	2023-06-28	Minakem	Process for the preparation of rilpivirine
MX2022000060A (en) *	2019-07-03	2022-04-18	Janssen Sciences Ireland Unlimited Co	Methods of treating hiv in pediatric patients with rilpivirine.
CN110526873B (en) *	2019-08-15	2022-09-16	复旦大学	Cyanovinyl substituted benzodiarylpyrimidine compound and preparation method and application thereof
EP4065121A4 (en)	2019-11-29	2023-11-29	Aptorum Therapeutics Limited	Composition including rilpivirine and use thereof for treating tumors or cancer
CN111004215B (en) *	2019-12-22	2022-08-09	华北理工大学	2, 4-substituted pyrimidine derivatives, preparation method thereof and application thereof in preparing antitumor drugs
CN111217833B (en) *	2020-02-21	2021-03-16	山东大学	Thieno [2,3-d ] pyrimidine HIV-1 non-nucleoside reverse transcriptase inhibitor and preparation method and application thereof
US20230310427A1 (en) *	2020-06-30	2023-10-05	University Of South Australia	New therapeutic use of rilpivirine
CN112028836B (en) *	2020-09-09	2021-12-07	山东大学	Diarylpyrimidine derivative containing six-membered nitrogen heterocycle and preparation method and application thereof
CN112010810B (en) *	2020-09-09	2024-01-30	瑞阳制药股份有限公司	Method for preparing high-purity rilpivirine intermediate by one-pot method
WO2022079739A1 (en)	2020-10-14	2022-04-21	Cipla Limited	Fixed dose compositions of cabotegravir and rilpivirine
UY39520A (en)	2020-11-17	2022-05-31	Janssen Sciences Ireland Unlimited Co	TREATMENT OR PREVENTION OF HIV INFECTION
CN112546969B (en) *	2020-12-07	2022-12-23	安徽贝克制药股份有限公司	Catalytic hydrogenation continuous production device and preparation method of ritonavir intermediate
CN112778214A (en) *	2021-01-13	2021-05-11	安徽贝克联合制药有限公司	Intermediate for synthesizing rilpivirine, synthesis method thereof and rilpivirine synthesis method
CN113105394A (en) *	2021-03-08	2021-07-13	复旦大学	Biphenyl diaryl pyrimidine derivative containing aromatic heterocyclic structure and preparation method and application thereof
CN113461666A (en) *	2021-05-06	2021-10-01	复旦大学	Biphenyl diaryl methyl pyrimidine derivative containing aromatic heterocyclic structure and preparation method thereof
CN113845515A (en) *	2021-09-03	2021-12-28	复旦大学	Aromatic heterocyclic structure-containing dimethyl biphenyl diaryl pyrimidine derivative and preparation method and application thereof
WO2023088964A1 (en)	2021-11-17	2023-05-25	Janssen Sciences Ireland Unlimited Company	Dissolution test
WO2023203258A1 (en)	2022-04-22	2023-10-26	Janssen Sciences Ireland Unlimited Company	Liquid compositions
WO2023203255A1 (en)	2022-04-22	2023-10-26	Janssen Sciences Ireland Unlimited Company	Freeze dried compositions
WO2023222754A1 (en)	2022-05-17	2023-11-23	Janssen Sciences Ireland Unlimited Company	Rilpivirine for use in the treatment or prevention of hiv infection
WO2023222755A1 (en)	2022-05-17	2023-11-23	Janssen Sciences Ireland Unlimited Company	Treatment or prevention of hiv infection
CN115490642A (en) *	2022-09-21	2022-12-20	山东大学	Diaryl pyrimidine compound containing ether bond and preparation method and application thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3459731A (en)	1966-12-16	1969-08-05	Corn Products Co	Cyclodextrin polyethers and their production
US3953398A (en) *	1970-07-20	1976-04-27	The Goodyear Tire & Rubber Company	Age resistant polymeric compositions
JPS63159316A (en) *	1977-11-28	1988-07-02	アルキユサル　インコーポレーテツド　ピーテイワイ　リミテツド	Antiinflammatory composition containing neutral copper bonded body
EP0002341B1 (en) *	1977-11-28	1982-01-20	Barry Boettcher	Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes
JPS5879920A (en) *	1981-11-09	1983-05-13	Kanegafuchi Chem Ind Co Ltd	Inhibitor against blood platelet aggregation
GB9012592D0 (en)	1990-06-06	1990-07-25	Smithkline Beecham Intercredit	Compounds
US5318780A (en) *	1991-10-30	1994-06-07	Mediventures Inc.	Medical uses of in situ formed gels
US5691364A (en)	1995-03-10	1997-11-25	Berlex Laboratories, Inc.	Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) *	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
CZ154398A3 (en)	1995-11-23	1998-08-12	Janssen Pharmaceutica N.V.	Solid mixtures of cyclodextrins prepared by melt extrusion
TW429256B (en)	1995-12-27	2001-04-11	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
GB9705361D0 (en)	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
JP3990808B2 (en) *	1998-03-26	2007-10-17	Ｔｄｋ株式会社	Method for producing electrode for non-aqueous electrolyte battery
BRPI9909191B8 (en) *	1998-03-27	2021-07-06	Janssen Pharmaceutica Nv	hiv inhibitor pyrimidine derivatives, their use and pharmaceutical composition comprising them
EP0945447A1 (en) *	1998-03-27	1999-09-29	Janssen Pharmaceutica N.V.	Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
DK0945443T3 (en)	1998-03-27	2003-06-02	Janssen Pharmaceutica Nv	HIV inhibitory pyrimidine derivatives
JP2000035628A (en) *	1998-07-16	2000-02-02	Konica Corp	Silver halide photographic sensitive material
WO2000012485A1 (en) *	1998-08-29	2000-03-09	Astrazeneca Ab	Pyrimidine compounds
UA70966C2 (en)	1998-11-10	2004-11-15	Янссен Фармацевтика Н.В.	Pirimidines inhibiting hiv replication
DK1159279T3 (en)	1999-03-09	2003-02-17	Upjohn Co	4-Oxo-4,7-dihydro-thieno [2,3-b] pyridine-5-carboxamides as antivirals
KR100710100B1 (en)	1999-04-15	2007-04-23	브리스톨-마이어스스퀴브컴파니	Cyclic Protein Tyrosine Kinase Inhibitors
GB9914258D0 (en)	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
OA12029A (en) *	1999-09-24	2006-04-28	Janssen Pharmaceutica Nv	Antiviral compositions.
DE19945982A1 (en) *	1999-09-24	2001-03-29	Knoll Ag	Velocity-determined particles
AU3704101A (en) *	2000-02-17	2001-08-27	Amgen Inc	Kinase inhibitors
GB0004887D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004888D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
JP4969010B2 (en)	2000-05-08	2012-07-04	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Prodrug of HIV replication inhibitory pyrimidine
JP5230050B2 (en)	2000-05-08	2013-07-10	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	HIV replication inhibitor
US6596729B2 (en) *	2000-07-20	2003-07-22	Bristol-Myers Squibb Company	Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
EP1363877A2 (en) *	2001-03-02	2003-11-26	SmithKline Beecham Corporation	Benzophenones as inhibitors of reverse transcriptase
MXPA03008888A (en) *	2001-03-29	2005-03-07	Vertex Pharma	Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases.
JO3429B1 (en) *	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	Hiv inhibiting pyrimidines derivatives
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en)	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) *	2001-08-13	2012-01-24	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AU2002329842B2 (en) *	2001-08-29	2006-09-14	Umd, Inc.	Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
TWI329105B (en) *	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
EA008244B1 (en) *	2002-05-03	2007-04-27	Янссен Фармацевтика Н.В.	Polymeric microemulsions
AU2003266413B2 (en)	2002-08-09	2009-04-02	Janssen Pharmaceutica N.V.	Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AU2002350719A1 (en)	2002-11-29	2004-06-23	Janssen Pharmaceutica N.V.	Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US20070021449A1 (en) *	2003-02-07	2007-01-25	Jan Heeres	Pyrimidine derivatives for the prevention of hiv infection
WO2011103559A1 (en) *	2010-02-22	2011-08-25	Nektar Therapeutics	Oligomer modified diaromatic substituted compounds

2002
- 2002-07-16 JO JOP/2002/0074A patent/JO3429B1/en active
- 2002-08-09 NZ NZ530951A patent/NZ530951A/en not_active IP Right Cessation
- 2002-08-09 AT AT02764839T patent/ATE517891T1/en active
- 2002-08-09 BR BR122015023612A patent/BR122015023612B8/en not_active IP Right Cessation
- 2002-08-09 SI SI200231101T patent/SI3808743T1/en unknown
- 2002-08-09 EP EP10178189.6A patent/EP2298761B1/en not_active Expired - Lifetime
- 2002-08-09 HU HU0401346A patent/HU230192B1/en active Protection Beyond IP Right Term
- 2002-08-09 CN CN200910145401.5A patent/CN101816658B/en not_active Expired - Lifetime
- 2002-08-09 AP APAP/P/2004/002993A patent/AP1610A/en active
- 2002-08-09 KR KR1020077022611A patent/KR100969273B1/en active Protection Beyond IP Right Term
- 2002-08-09 ES ES20165399T patent/ES2923581T3/en not_active Expired - Lifetime
- 2002-08-09 ES ES10178189T patent/ES2799408T3/en not_active Expired - Lifetime
- 2002-08-09 EA EA200400304A patent/EA006656B1/en active IP Right Maintenance
- 2002-08-09 PL PL402388A patent/PL402388A1/en unknown
- 2002-08-09 SI SI200230963T patent/SI1419152T1/en unknown
- 2002-08-09 ES ES02764839T patent/ES2368996T3/en not_active Expired - Lifetime
- 2002-08-09 DK DK02764839.3T patent/DK1419152T3/en active
- 2002-08-09 US US10/485,636 patent/US7125879B2/en active Active
- 2002-08-09 KR KR1020047000372A patent/KR100817453B1/en active IP Right Review Request
- 2002-08-09 HR HRP20192051AA patent/HRP20192051B1/en not_active IP Right Cessation
- 2002-08-09 AU AU2002329238A patent/AU2002329238C1/en active Active
- 2002-08-09 BR BRPI0211909-9 patent/BRPI0211909B8/en active IP Right Grant
- 2002-08-09 PL PL368270A patent/PL216398B1/en unknown
- 2002-08-09 CA CA002452217A patent/CA2452217C/en not_active Expired - Lifetime
- 2002-08-09 CN CNB028159209A patent/CN100509801C/en not_active Expired - Lifetime
- 2002-08-09 HU HU1900370A patent/HU231274B1/en active Protection Beyond IP Right Term
- 2002-08-09 BR BR122015032641-9A patent/BR122015032641B1/en not_active IP Right Cessation
- 2002-08-09 EP EP20165399.5A patent/EP3808743B1/en not_active Expired - Lifetime
- 2002-08-09 MY MYPI20071005A patent/MY189572A/en unknown
- 2002-08-09 JP JP2003521229A patent/JP2005507380A/en not_active Withdrawn
- 2002-08-09 PT PT02764839T patent/PT1419152E/en unknown
- 2002-08-09 MX MXPA04001401A patent/MXPA04001401A/en active IP Right Grant
- 2002-08-09 EP EP02764839A patent/EP1419152B1/en not_active Expired - Lifetime
- 2002-08-09 DK DK20165399.5T patent/DK3808743T3/en active
- 2002-08-09 OA OA1200400047A patent/OA12652A/en unknown
- 2002-08-09 IL IL16032802A patent/IL160328A0/en active IP Right Grant
- 2002-08-09 LT LTEP20165399.5T patent/LT3808743T/en unknown
- 2002-08-09 WO PCT/EP2002/008953 patent/WO2003016306A1/en active Application Filing
- 2002-08-10 EG EG2002080892A patent/EG24684A/en active
- 2002-08-12 PA PA20028552901A patent/PA8552901A1/en unknown
- 2002-08-12 AR ARP020103034A patent/AR036387A1/en active IP Right Grant
- 2002-09-08 UA UA2004031903A patent/UA78221C2/en unknown
2004
- 2004-01-29 HR HRP20040096AA patent/HRP20040096B1/en not_active IP Right Cessation
- 2004-02-11 IL IL160328A patent/IL160328A/en active Protection Beyond IP Right Term
- 2004-02-12 ZA ZA2004/01159A patent/ZA200401159B/en unknown
- 2004-02-12 NO NO20040633A patent/NO327639B1/en not_active IP Right Cessation
2005
- 2005-04-01 HK HK05102760.9A patent/HK1070066A1/en not_active IP Right Cessation
2006
- 2006-06-26 US US11/474,855 patent/US8080551B2/en not_active Expired - Fee Related
2008
- 2008-09-02 NO NO20083770A patent/NO337142B1/en not_active IP Right Cessation
2009
- 2009-11-12 JP JP2009259107A patent/JP5247661B2/en not_active Expired - Lifetime
2010
- 2010-12-21 HK HK10111939.9A patent/HK1145449A1/en not_active IP Right Cessation
2011
- 2011-06-16 JP JP2011134088A patent/JP4838396B2/en not_active Expired - Lifetime
- 2011-06-17 JP JP2011135468A patent/JP5539927B2/en not_active Expired - Lifetime
- 2011-09-30 US US13/249,796 patent/US20120076835A1/en not_active Abandoned
- 2011-10-26 CY CY20111101014T patent/CY1112331T1/en unknown
2012
- 2012-03-23 HR HRP20120265A patent/HRP20120265B1/en not_active IP Right Cessation
- 2012-05-08 BE BE2012C020C patent/BE2012C020I2/nl unknown
- 2012-05-16 LU LU92001C patent/LU92001I2/en unknown
- 2012-05-18 CY CY2012012C patent/CY2012012I1/en unknown
- 2012-05-22 FR FR12C0035C patent/FR12C0035I2/en active Active
- 2012-05-23 NO NO2012010C patent/NO2012010I2/en unknown
- 2012-05-24 BE BE2012C022C patent/BE2012C022I2/nl unknown
- 2012-05-24 LU LU92008C patent/LU92008I2/en unknown
- 2012-05-25 DE DE201212000038 patent/DE122012000038I1/en active Pending
- 2012-05-25 CY CY2012013C patent/CY2012013I2/en unknown
- 2012-05-25 FR FR12C0036C patent/FR12C0036I2/en active Active
2014
- 2014-08-05 US US14/451,761 patent/US9580392B2/en not_active Expired - Lifetime
2015
- 2015-10-20 HU HUS1500051C patent/HUS1500051I1/en unknown
2016
- 2016-02-03 HU HUS1500055C patent/HUS1500055I1/en unknown
2017
- 2017-01-16 US US15/406,918 patent/US20170121292A1/en not_active Abandoned
- 2017-07-20 US US15/655,570 patent/US9981919B2/en not_active Expired - Lifetime
2018
- 2018-04-26 US US15/963,352 patent/US10370340B2/en not_active Expired - Fee Related
2019
- 2019-07-02 US US16/460,898 patent/US10611732B2/en not_active Expired - Lifetime
2022
- 2022-07-27 FR FR22C1036C patent/FR22C1036I1/en active Active
- 2022-07-28 BE BE2022C531C patent/BE2022C531I2/nl unknown
- 2022-08-02 HU HUS2200038C patent/HUS2200038I1/en unknown
- 2022-08-02 LT LTPA2022515C patent/LTC3808743I2/lt unknown

Also Published As

Publication number	Publication date
EP2298761B1 (en)	2020-03-25
CN101816658A (en)	2010-09-01
BR122015023612B8 (en)	2021-05-25
JP5539927B2 (en)	2014-07-02
NO20040633L (en)	2004-03-12
MXPA04001401A (en)	2004-05-27
US20190322628A1 (en)	2019-10-24
US10370340B2 (en)	2019-08-06
JP2011236221A (en)	2011-11-24
NO337142B1 (en)	2016-02-01
AU2002329238B2 (en)	2008-01-24
EA006656B1 (en)	2006-02-24
HRP20120265B1 (en)	2019-11-29
ZA200401159B (en)	2005-07-27
JP2005507380A (en)	2005-03-17
NO20083770L (en)	2004-03-12
JO3429B1 (en)	2019-10-20
US20040198739A1 (en)	2004-10-07
BE2012C022I2 (en)	2022-01-12
WO2003016306A1 (en)	2003-02-27
PL216398B1 (en)	2014-03-31
HUP0401346A3 (en)	2009-03-02
US8080551B2 (en)	2011-12-20
ATE517891T1 (en)	2011-08-15
HK1070066A1 (en)	2005-06-10
CN101816658B (en)	2014-08-27
EP1419152B1 (en)	2011-07-27
IL160328A0 (en)	2004-07-25
AP1610A (en)	2006-05-08
NO2012010I1 (en)	2012-06-18
CN1541215A (en)	2004-10-27
HUS1500051I1 (en)	2018-05-28
CY2012013I1 (en)	2015-08-05
BR0211909A (en)	2004-08-24
PA8552901A1 (en)	2003-02-28
BR122015023612B1 (en)	2021-01-19
HRP20192051A2 (en)	2020-03-06
BRPI0211909B8 (en)	2021-05-25
CY2012012I2 (en)	2015-08-05
US20170121292A1 (en)	2017-05-04
HRP20192051B1 (en)	2022-05-27
NZ530951A (en)	2005-10-28
SI3808743T1 (en)	2022-09-30
US20120076835A1 (en)	2012-03-29
PL402388A1 (en)	2013-04-02
US20140343006A1 (en)	2014-11-20
CN100509801C (en)	2009-07-08
EA200400304A1 (en)	2004-08-26
JP2011225589A (en)	2011-11-10
HU231274B1 (en)	2022-07-28
US20180244632A1 (en)	2018-08-30
JP2010077140A (en)	2010-04-08
US9981919B2 (en)	2018-05-29
LU92008I2 (en)	2012-07-24
BR122015032641B1 (en)	2022-03-03
HUP0401346A2 (en)	2004-12-28
NO2012010I2 (en)	2013-09-02
LU92001I2 (en)	2012-07-16
NO327639B1 (en)	2009-09-07
US20170320835A1 (en)	2017-11-09
HRP20040096B1 (en)	2013-06-30
LTPA2022515I1 (en)	2022-08-25
FR12C0036I2 (en)	2016-05-06
BRPI0211909B1 (en)	2018-05-29
KR100817453B1 (en)	2008-03-27
OA12652A (en)	2006-06-15
HUS2200038I1 (en)	2022-08-28
CY2012012I1 (en)	2015-08-05
CY1112331T1 (en)	2015-08-05
DK3808743T3 (en)	2022-08-01
ES2368996T3 (en)	2011-11-24
AU2002329238C1 (en)	2008-08-28
MY189572A (en)	2022-02-17
AR036387A1 (en)	2004-09-08
EP2298761A1 (en)	2011-03-23
KR100969273B1 (en)	2010-08-20
UA78221C2 (en)	2007-03-15
FR12C0036I1 (en)	2012-06-29
US10611732B2 (en)	2020-04-07
KR20040023645A (en)	2004-03-18
CA2452217A1 (en)	2003-02-27
EP1419152A1 (en)	2004-05-19
EP3808743B1 (en)	2022-07-20
US7125879B2 (en)	2006-10-24
JP5247661B2 (en)	2013-07-24
JP4838396B2 (en)	2011-12-14
KR20070101409A (en)	2007-10-16
HRP20120265A2 (en)	2012-05-31
FR12C0035I2 (en)	2016-02-12
DK1419152T3 (en)	2011-10-24
HU230192B1 (en)	2015-09-28
EP3808743A1 (en)	2021-04-21
AP2004002993A0 (en)	2004-03-31
HK1145449A1 (en)	2011-04-21
PT1419152E (en)	2011-10-11
ES2923581T3 (en)	2022-09-28
SI1419152T1 (en)	2011-11-30
PL368270A1 (en)	2005-03-21
US20060252764A1 (en)	2006-11-09
LT3808743T (en)	2022-08-10
LTC3808743I2 (en)	2023-04-25
US9580392B2 (en)	2017-02-28
HUS1500055I1 (en)	2016-03-29
IL160328A (en)	2011-01-31
BE2022C531I2 (en)	2022-08-09
BE2012C020I2 (en)	2021-07-19
CY2012013I2 (en)	2015-08-05
ES2799408T3 (en)	2020-12-17
DE122012000038I1 (en)	2012-09-20
FR12C0035I1 (en)	2012-06-22
CA2452217C (en)	2009-06-16
EG24684A (en)	2010-05-05
HRP20040096A2 (en)	2004-06-30

Publication	Publication Date	Title
FR22C1036I1 (en)	2022-09-09	PYRIMIDINE DERIVATIVES AS HIV INHIBITOR
FR20C1039I2 (en)	2021-08-13	DERIVATIVES OF UK-2A
FR15C0086I2 (en)	2016-06-03	HYDROXAMATE DERIVATIVES AS DESACETYLASE INHIBITORS
MA26994A1 (en)	2004-12-20	QUINAZOLINES AS INHIBITORS OF MMP-13
MA26972A1 (en)	2004-12-20	TETRALONE DERIVATIVES AS ANTI-TUMOR AGENTS
NO20042279L (en)	2004-06-02	Quinazoline derivatives as antitumor agents
NO20042288L (en)	2004-06-03	Quinazoline derivatives as antitumor agents
DZ3425A1 (en)	2002-03-21	QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS
EE200300497A (en)	2004-02-16	Pyrazole derivatives for the treatment of HIV
NO20033969D0 (en)	2003-09-08	Triazole pyridines as anti-inflammatory agents
MA26932A1 (en)	2004-12-20	DERIVATIVES OF IMIDAZOLE.
MA26782A1 (en)	2004-12-20	PYRAZOLOBENZODIAZEPINES AS CDK2 INHIBITORS.
DK1412328T3 (en)	2007-02-12	Dolastatin-10 derivatives
DE50104135D1 (en)	2004-11-18	AQUEOUS COMPOSITIONS
DE60015388D1 (en)	2004-12-02	COMPOSITION OF ITEMS OBTAINED FROM IT
MA27046A1 (en)	2004-12-20	NEW OXAZOLIDINON DERIVATIVES AS ANTIBACTERIAL AGENTS.
FR2813756B1 (en)	2003-03-07	DILUENT FOR THE CONSERVATION OF SWINE SPERMATOZOIDES
IT1324892B (en)	2004-12-02	MIXTURES OF STABILIZING AGENTS
ATE450652T1 (en)	2009-12-15	AQUEOUS COMPOSITION
MA27094A1 (en)	2004-12-20	TRIAZOLO-QUINOLINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR LIGANDS.
IT1324893B (en)	2004-12-02	MIXTURES OF STABILIZING AGENTS
MA27240A1 (en)	2005-03-01	IMIDAZOQUINOLEIN DERIVATIVES
DZ3344A1 (en)	2001-11-29	SULFONAMIDE DERIVATIVES
DE60201463D1 (en)	2004-11-11	Indanon derivatives as fragrances
ITMI20011633A0 (en)	2001-07-27	USE OF SUPERSULFATED BACTERIAL POLYSACCHARIDES HIV INHIBITORS